drugset / Trial / NCT07535437
A Study of Ivonescimab in Combination With Dato-DXd or Osimertinib in People With Non-Small Cell Lung Cancer
Phase 1/2
Recruiting
66 enrolled
Memorial Sloan Kettering Cancer Center
Summit Therapeutics · collab
Non-randomizedSequentialOpen-labelTreatment
Summary
The researchers are doing this study to find out whether ivonescimab in combination with datopotamab deruxtecan- (Dato-DXd) or osimertinib are safe and effective treatments in people with non-small cell lung cancer (NSCLC) that has an EGFR mutation. The researchers will test different doses of the Dato-DXd or osimertinib with an unchanging (fixed) dose of ivonescimab to find the best dose that causes few or mild side effects in participants. Once the dose is found the researchers will test ivonescimab with Dato-DXd or osimertinib in a new group of participants to see if it is effective in treating their NSCLC with an EGFR mutation.
Timeline
- Start
- 2026-04-09
- Primary completion
- 2028-04
- Completion
- 2028-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Datopotamab deruxtecan | Monoclonal antibody | 4 mg/kg | — |
| Subject | Datopotamab deruxtecan | Monoclonal antibody | 6 mg/kg | — |
| Subject | Ivonescimab | Monoclonal antibody | 20 mg/kg | — |
| Subject | Osimertinib | Small molecule | 40 mg | — |
| Subject | Osimertinib | Small molecule | 80 mg | — |